Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Sees Large Decline in Short Interest

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) saw a significant decline in short interest during the month of February. As of February 15th, there was short interest totalling 10,400 shares, a decline of 46.1% from the January 31st total of 19,300 shares. Currently, 0.7% of the company’s stock are sold short. Based on an average daily volume of 2,030,000 shares, the short-interest ratio is presently 0.0 days.

Salarius Pharmaceuticals Price Performance

NASDAQ:SLRX traded down $0.15 during trading hours on Friday, hitting $1.08. 257,839 shares of the company were exchanged, compared to its average volume of 3,351,676. The company’s 50 day moving average price is $1.93 and its 200-day moving average price is $1.69. The stock has a market capitalization of $1.71 million, a price-to-earnings ratio of -0.13 and a beta of 0.84. Salarius Pharmaceuticals has a 52-week low of $0.91 and a 52-week high of $7.20.

About Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.